Literature DB >> 25663412

Natalizumab-associated cerebellar PML: a case report on how to slow down IRIS.

F Lauda1, T Fangerau, K Javaheripour-Otto, E Pinkhardt, J Kassubek, H Tumani.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25663412     DOI： 10.1007/s00415-015-7658-y

Source DB:  PubMed          Journal:  J Neurol        ISSN： 0340-5354            Impact factor:   4.849


× No keyword cloud information.
  12 in total

Review 1.  Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases.

Authors:  David B Clifford; Andrea De Luca; Andrea DeLuca; David M Simpson; Gabriele Arendt; Gavin Giovannoni; Avindra Nath
Journal:  Lancet Neurol       Date:  2010-04       Impact factor: 44.182

2.  Immune reconstitution inflammatory syndrome in natalizumab-associated PML.

Authors:  I L Tan; J C McArthur; D B Clifford; E O Major; A Nath
Journal:  Neurology       Date:  2011-08-10       Impact factor: 9.910

3.  Cerebrospinal fluid parameters of B cell-related activity in patients with active disease during natalizumab therapy.

Authors:  A Harrer; H Tumani; S Niendorf; F Lauda; C Geis; A Weishaupt; C Kleinschnitz; S Rauer; J Kuhle; M Stangel; F Weber; M Uhr; M Linnebank; B Wildemann; S Jarius; M Guger; I Ayzenberg; A Chan; U Zettl; H Wiendl; G Pilz; W Hitzl; J R Weber; J Kraus
Journal:  Mult Scler       Date:  2012-10-23       Impact factor: 6.312

Review 4.  PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section.

Authors:  Joseph R Berger; Allen J Aksamit; David B Clifford; Larry Davis; Igor J Koralnik; James J Sejvar; Russell Bartt; Eugene O Major; Avindra Nath
Journal:  Neurology       Date:  2013-04-09       Impact factor: 9.910

5.  Clinical and paraclinical findings in natalizumab-associated infratentorial progressive multifocal leukoencephalopathy patients.

Authors:  R Hoepner; J Ahlbrecht; S Faissner; R Schneider; S Dahlhaus; O Adams; P Raab; C Lukas; A Chan; M Stangel; R Gold
Journal:  J Neurol Neurosurg Psychiatry       Date:  2014-04-03       Impact factor: 10.154

6.  Treatment of progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome with intravenous immunoglobulin in a patient with multiple sclerosis treated with fingolimod after discontinuation of natalizumab.

Authors:  Z Calic; C Cappelen-Smith; S J Hodgkinson; A McDougall; R Cuganesan; B J Brew
Journal:  J Clin Neurosci       Date:  2014-12-15       Impact factor: 1.961

Review 7.  Potential risk of progressive multifocal leukoencephalopathy with natalizumab therapy: possible interventions.

Authors:  Olaf Stüve; Christina M Marra; Petra D Cravens; Mahendra P Singh; Wei Hu; Amy Lovett-Racke; Nancy L Monson; J Theodore Phillips; Jan W Cohen Tervaert; Richard A Nash; Hans-Peter Hartung; Bernd C Kieseier; Michael M Racke; Elliot M Frohman; Bernhard Hemmer
Journal:  Arch Neurol       Date:  2007-02

8.  Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function.

Authors:  B O Khatri; S Man; G Giovannoni; A P Koo; J-C Lee; B Tucky; F Lynn; S Jurgensen; J Woodworth; S Goelz; P W Duda; M A Panzara; R M Ransohoff; R J Fox
Journal:  Neurology       Date:  2009-02-03       Impact factor: 9.910

9.  Progressive multifocal leukoencephalopathy after natalizumab monotherapy.

Authors:  Hans Lindå; Anders von Heijne; Eugene O Major; Caroline Ryschkewitsch; Johan Berg; Tomas Olsson; Claes Martin
Journal:  N Engl J Med       Date:  2009-09-10       Impact factor: 91.245

10.  Disease course and outcome of 15 monocentrically treated natalizumab-associated progressive multifocal leukoencephalopathy patients.

Authors:  Stefanie Dahlhaus; Robert Hoepner; Andrew Chan; Ingo Kleiter; Ortwin Adams; Carsten Lukas; Kerstin Hellwig; Ralf Gold
Journal:  J Neurol Neurosurg Psychiatry       Date:  2013-04-19       Impact factor: 10.154
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.